Lancell, LLC Receives CCAT(SM) Award.

SAN DIEGO -- The Center for Commercialization of Advanced Technology (CCAT) in San Diego, California announced today that the Center has granted Lancell, LLC a $75,000 product development award for its vaccine acceleration technology. Additionally, CCAT has granted the company two business support awards that include a market study and commercialization planning assistance to facilitate business development activities. E[acute accent]San Diego-based Lancell is in the process of developing a molecular treatment that activates dendritic cells when applied topically to the skin over a vaccine injection site. The vaccine, combined with the Lancell treatment, activates strong, rapid T cell immunity and may also induce strong, rapid antibody protection that accelerates the vaccine's effectiveness. This treatment can be used with any type of current vaccine, as well as those that are under development (the much anticipated avian flu vaccine, for example). Additionally, Lancell's technology can be used to speed protection for inoculations against bioterrorist threats including anthrax and smallpox. E[acute accent]"Lancell's technology is critical because current vaccines work too slowly. An individual can be infected and the illness can take hold before the vaccine has had sufficient time to establish immunity," said Dr. Carol Cowing, CEO of Lancell, LLC. "CCAT's support will play a crucial role in helping to get our efforts into clinical trials. If our endeavors are successful, the technology will be an inexpensive method of accelerating vaccination protection before the illness has the opportunity to take hold in individuals and spread among the population at large." E[acute accent]Funded by the Department of Defense (DoD), the CCAT program offers funding and business development to small business entrepreneurs, government labs and academic researchers to speed commercialization of technology needed by the DoD and the Department of Homeland Security (DHS). E[acute accent]"The value of Lancell's procedure lies in its potential to induce rapid T cell and antibody immunity to every type of vaccine without costly individualized processes," said Tom Sheffer, program director for CCAT at San Diego State University (SDSU) Research Foundation. "CCAT looks forward to working closely with Lancell to offer support in building their business and fast tracking their technology into the marketplace."

E[acute accent]ABOUT THE CENTER FOR COMMERCIALIZATION OF ADVANCED TECHNOLOGY

E[acute accent]The Center for Commercialization of Advanced Technology (CCAT) is supported by Congress and funded by the Department of Defense as a public-private collaborative partnership between academia, industry, and government. With Centers located at California State University, San Bernardino (CSUSB) and San Diego State University (SDSU), the CCAT program provides funding and business development support services to small entrepreneurs, small businesses, government/university research scientists that have developed technology for use in the Departments of Defense and Homeland Security, as well as the commercial marketplace. Additional program partners include the University of California, San Diego (UCSD) Jacobs School of Engineering, CONNECT, and Lockheed Martin ORINCON Technologies, Inc. with support from the Space and Naval Warfare Systems Center, San Diego (SSC San Diego). For more information about CCAT, visit www.ccatsocal.org.